

Product Data Sheet

Product Name: Berobenatide acetate

Cat. No.: GC79206

Chemical Properties

Cas. No.

Formula $C_{232}H_{369}N_{57}O_{68} \cdot xC_2H_4O_2$ M.Wt 5044.75

Solubility DMSO: 10 mg/mL (Need ultrasonic) Storage Sealed storage, away from moisture

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

Berobenatide acetate (PF-08653944 acetate; MET-097 acetate) is a GLP-1R agonist that exerts functional regulation of GLP-1R biased toward the Gs protein signaling pathway. Berobenatide acetate induces weight loss in diet-induced obese mice. Berobenatide acetate can be used in

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

obesity-related research [1] [2].

In Vivo, Bero benatide (0.24-0.8 nmol/kg; subcutaneous injection; once daily; administered for 22 days, with double doses on day 7 and day 14) acetate induces a significantly greater body weight loss in DIO mice than Semaglutide and Tirzepatide [1].

References:

- [1]. Hinds C, et al. MET-097: Preclinical Characterization of a Potent and Ultra-Long-Acting GLP-1 Receptor Agonist. *Diabetes*, 2025, 74(Supplement_1): 794-P.
- [2]. Lee S, et al. A Lineup for Next Anti-Obesity Medicines: Beyond Incretin-Based Pharmacotherapy. *Pharmaceuticals* (Basel, Switzerland). 2026 Jul 07;19(7):1047.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA